Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06328608 · ClinicalTrials.gov registry record · Phase 2
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
A Phase 2 study of Fabry Disease, sponsored by Chiesi Farmaceutici S.p.A..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 12
- Study locations
NCT06328608 is a Phase 2 study of Fabry Disease that is actively recruiting participants, run by Chiesi Farmaceutici S.p.A.. The registered enrollment target is 22 participants, below the 542-participant average among 32 other Fabry Disease trials with a reported enrollment target (96% lower). The trial reports 12 study locations across 7 states.
The verdict
NCT06328608, a Phase 2 study of Fabry Disease, is actively recruiting participants, sponsored by Chiesi Farmaceutici S.p.A..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 12
- Study locations
Study Summary
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents with Fabry Disease.
Conditions Studied
Interventions
- DRUG PRX-102 1 mg/kg every two weeks
Study Locations (12)
Other
- UK für Kinder- und Jugendheilkunde der PMU Salzburg - Salzburg
- Centre Hospitalier Universitaire (CHU) de Bordeaux - Groupe Hospitalier Pellegrin - Bordeaux
- Hopital Arnaud de Villeneuve - Montpellier
- Haukeland Universitetssjukehus - Bergen
- Hospital Clinico Universitario De Santiago De Compostela - Santiago de Compostela
- Great Ormond Street Hospital for Children NHS Foundation Trust - London
Arizona
- Phoenix Children's - Phoenix
Georgia
- Emory Genetics Clinical Trials Center - Atlanta
Iowa
- University of Iowa - Iowa City
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Utah
- University of Utah - Salt Lake City
Virginia
- Lysosomal and Rare Disorders Research and Treatment Center Inc - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2025-07-29 |
| Est. Completion | 2031-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06328608
The ClinicalTrials.gov registry entry for NCT06328608 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 542-participant average among 32 other Fabry Disease trials with a reported enrollment target (96% lower). The listed sponsor is Chiesi Farmaceutici S.p.A., which has 30 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fabry Disease appearing as the primary indexed condition, and to 1 intervention - of which PRX-102 1 mg/kg every two weeks is the first listed.
NCT06328608 reports 12 study locations spanning 7 distinct geographic areas - top geographies include Other, Arizona, Georgia.
Frequently Asked Questions
What is clinical trial NCT06328608 about?
NCT06328608 is a clinical study titled "A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease". A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents with Fabry Disease.
What is the current status of trial NCT06328608?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2025-07-29. Estimated completion is 2031-04.
What conditions does trial NCT06328608 study?
This clinical trial studies the following conditions: Fabry Disease.
What interventions are being tested in trial NCT06328608?
The interventions under investigation include: PRX-102 1 mg/kg every two weeks (DRUG).
Who is sponsoring clinical trial NCT06328608?
This trial is sponsored by Chiesi Farmaceutici S.p.A., which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06328608 being conducted?
This trial has 12 study locations across Arizona, Georgia, Iowa, Ohio, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fabry Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease
COMPLETED · Phase 2
-
Dosing Study of Replagal in Patients With Fabry Disease
COMPLETED · Phase 2
-
Alternative Dosing and Regimen of Replagal to Treat Fabry Disease
COMPLETED · Phase 2
-
An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease
COMPLETED · Phase 2
-
Safety Study of Replagal® Therapy in Children With Fabry Disease
COMPLETED · Phase 2
-
Alpha-Galactosidase A Replacement Therapy for Fabry Disease
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.